ELEDON PHARMACEUTICALS INC

Eledon Pharmaceuticals is a clinical-stage biotechnology company whose core business model involves conducting animal testing as a required component of its drug development process. The company’s lead investigational drug, tegoprubart, and its pipeline candidates require preclinical studies that assess toxicology, pharmacokinetics, and pharmacology in animal models, as documented in its Investigational New Drug (IND) submissions to the U.S. Food and Drug Administration. This reliance on animal experimentation is inherent to its business of developing biologic therapies for organ transplantation and autoimmune diseases.

The evidence gathered from SEC filings and company disclosures is general, referencing standard preclinical animal and in vitro studies. No specific, material details regarding the scale, species, or nature of the animal testing were found in the provided sources. As a result, this exclusion under the animal_exploitation category is based on the company's operational model as a clinical-stage biopharmaceutical entity, which necessitates animal testing for regulatory approval, rather than on documented incidents of particular cruelty or a pattern of violations.